KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 73 filers reported holding KALA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $94,000 | +16.0% | 68,051 | +2.2% | 0.00% | – |
| Q4 2021 | $81,000 | -53.7% | 66,591 | -0.0% | 0.00% | – |
| Q3 2021 | $175,000 | -49.1% | 66,621 | +2.8% | 0.00% | – |
| Q2 2021 | $344,000 | -11.1% | 64,824 | +12.9% | 0.00% | -100.0% |
| Q1 2021 | $387,000 | +3.5% | 57,406 | +4.0% | 0.00% | 0.0% |
| Q4 2020 | $374,000 | -4.8% | 55,182 | +5.4% | 0.00% | 0.0% |
| Q3 2020 | $393,000 | -38.1% | 52,372 | -13.3% | 0.00% | 0.0% |
| Q2 2020 | $635,000 | +114.5% | 60,397 | +79.4% | 0.00% | 0.0% |
| Q1 2020 | $296,000 | +164.3% | 33,659 | +11.4% | 0.00% | – |
| Q4 2019 | $112,000 | +2.8% | 30,219 | +5.9% | 0.00% | – |
| Q3 2019 | $109,000 | -35.1% | 28,539 | +8.3% | 0.00% | – |
| Q2 2019 | $168,000 | +4.3% | 26,342 | +35.6% | 0.00% | – |
| Q1 2019 | $161,000 | +114.7% | 19,430 | +27.4% | 0.00% | – |
| Q4 2018 | $75,000 | -49.3% | 15,256 | +41.6% | 0.00% | – |
| Q2 2018 | $148,000 | – | 10,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 771,790 | $5,788,000 | 5.46% |
| RA Capital Management | 10,874,613 | $81,560,000 | 1.49% |
| Mesirow Financial Investment Management, Inc. | 36,445 | $273,000 | 1.17% |
| Samsara BioCapital, LLC | 451,162 | $3,384,000 | 0.94% |
| Parkman Healthcare Partners LLC | 310,053 | $2,325,000 | 0.62% |
| Orbimed Advisors | 5,465,030 | $40,988,000 | 0.52% |
| Eventide Asset Management | 3,450,000 | $25,875,000 | 0.51% |
| Vivo Capital, LLC | 786,883 | $5,902,000 | 0.34% |
| Ikarian Capital, LLC | 451,531 | $3,387,000 | 0.24% |
| Matisse Capital | 50,300 | $377,000 | 0.15% |